Product
Rifampicin
Aliases
RIF, Rifampicin 600mg, Rifampicin capsule, Rifampicin Capsules (1 other aliases)
36 clinical trials
31 indications
Indication
HealthyIndication
Healthy Control ParticipantsIndication
Advanced Malignant NeoplasmIndication
NSCLCIndication
Respiratory Syncytial Virus InfectionsIndication
Solid TumorsIndication
lymphomaIndication
Non-HodgkinIndication
CancerIndication
Advanced Solid TumoursIndication
ANCA-associated VasculitisIndication
chronic kidney diseaseIndication
MyelofibrosisIndication
ImpotenceIndication
Healthy SubjectsIndication
Healthy SubjectIndication
Tuberculous MeningitisIndication
TuberculosisIndication
Kidney FailureIndication
Drug InteractionsIndication
PulmonaryIndication
HIVIndication
Tuberculous PericarditisIndication
Clinical TrialIndication
LeprosyIndication
Diabetes MellitusIndication
Type 2Indication
PneumoniaIndication
Mycobacterium Avium ComplexIndication
Pulmonary TuberculosisClinical trial
An Open-label, Fixed-sequence, Phase 1 Clinical Trial to Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy AdultsStatus: Completed, Estimated PCD: 2023-11-06
Clinical trial
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Phase I Study to Evaluate Drug-Drug Interaction of TQB3909 TabletsStatus: Not yet recruiting, Estimated PCD: 2024-01-01
Clinical trial
Effect of Rifampicin on the Pharmacokinetics of BI 409306 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed Sequence Trial)Status: Completed, Estimated PCD: 2017-07-11
Clinical trial
This is a Single-center, Two-sequence, Open-label, Two-cycle Drug-drug Interaction (DDI) Study in Healthy Subjects. To Evaluate the Effects of Itraconazole Capsules, a Strong Inhibitor of CYP3A4, and Rifampicin Capsules, a Strong Inducer, on the Pharmacokinetics of TY-9591 Tablets After a Single Oral DoseStatus: Recruiting, Estimated PCD: 2024-07-08
Clinical trial
An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid TumoursStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
An Adaptive, Part Open-label, Part Randomised Phase 1 Clinical Trial in Healthy Volunteers to Study Drug Interactions With RV521 Including Those Mediated by CYP3A4 and P-glycoproteinStatus: Completed, Estimated PCD: 2019-03-17
Clinical trial
Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy SubjectsStatus: Completed, Estimated PCD: 2023-12-19
Clinical trial
A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's LymphomasStatus: Terminated, Estimated PCD: 2024-03-25
Clinical trial
An Open-lable, Two- Period, Single-sequence, Self-controlled Study to Evaluate the Effect of Oral Rifampicin or Itraconazole on the Pharmacokinetics of ASK120067 TabletsStatus: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor), Rifampicin (a CYP3A4 Inducer), and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients With Advanced Solid TumoursStatus: Terminated, Estimated PCD: 2022-06-01
Clinical trial
An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsStatus: Completed, Estimated PCD: 2016-03-15
Clinical trial
An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or RifampicinStatus: Completed, Estimated PCD: 2020-11-23
Clinical trial
A Single-center, Non-randomized, Open-lable, Self-controlled Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy SubjectsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1,Parallel Assignment,Fixed-Sequence Study to Assess the Effect of Itraconazole, Rifampicin on the Pharmacokinetics of TPN171H in Healthy SubjectsStatus: Completed, Estimated PCD: 2020-04-27
Clinical trial
A Phase I Study to Evaluate Drug-Drug Interaction of TQ05105 TabletsStatus: Not yet recruiting, Estimated PCD: 2023-10-01
Clinical trial
A Single-center, Randomized, Double-blind, Two-period Cross-over Study to Investigate the Effect of a Single Intravenous Dose of Rifampicin on the Pharmacokinetics of ACT-246475 in Healthy SubjectsStatus: Completed, Estimated PCD: 2019-02-12
Clinical trial
Effect of Rifampicin on the Pharmacokinetics of a Single Oral Dose of BI 894416 in Healthy Male Subjects (an Open-label, One-way Crossover Study)Status: Completed, Estimated PCD: 2019-10-17
Clinical trial
Comparative Evaluation of Intensified Short Course Regimen and Standard Regimen for Adults TB Meningitis : an Open-label Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
Comparison of 3-month Once-weekly Isoniazid Plus Rifapentine, 4-month Daily Rifampicin, and 3-month Daily Isoniazid Plus Rifampicin for the Treatment Latent Tuberculosis in Patients With End-stage Kidney Disease: A Randomised Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-04-30
Clinical trial
An Open-label, Randomized Controlled Trial of the New One-month Regimen Versus the Current Three-month Regimen for the Treatment of Tuberculosis Infection in VietnamStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly SubjectsStatus: , Estimated PCD: 2024-10-24
Clinical trial
Pragmatic Trial on the Safety and Tolerability of an Optimized Dose of Rifampicin in Tuberculosis PatientsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST StudyStatus: Active (not recruiting), Estimated PCD: 2024-06-23
Clinical trial
IMPI-3 - A Randomized Controlled Trial of High vs. Standard Dose Rifampicin for Effusive Tuberculous PericarditisStatus: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary TuberculosisStatus: Recruiting, Estimated PCD: 2027-02-24
Clinical trial
Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampicin in Children With Newly Diagnosed Uncomplicated TuberculosisStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis: Improved Management With Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)Status: Recruiting, Estimated PCD: 2027-05-10
Clinical trial
A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisStatus: Not yet recruiting, Estimated PCD: 2025-06-10
Clinical trial
Post ExpOsure Prophylaxis for LEprosy in the Comoros and MadagascarStatus: Completed, Estimated PCD: 2023-01-31
Clinical trial
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive TuberculosisStatus: Completed, Estimated PCD: 2022-01-20
Clinical trial
Impact of LTBI Treatment on Glucose Tolerance and Chronic InflammationStatus: Completed, Estimated PCD: 2023-05-01
Clinical trial
An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary TuberculosisStatus: Completed, Estimated PCD: 2022-01-01
Clinical trial
A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)Status: Recruiting, Estimated PCD: 2025-09-23
Clinical trial
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung InfectionsStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Multiple Arm, Multiple Stage (MAMS), Phase 2B/C, Open Label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including an Increased Dose of Rifampicin, an Optimized Dose of Pyrazinamide, Moxifloxacin and BTZ-043, in Adults With Newly Diagnosed, Drug Sensitive, Smear-positive Pulmonary Tuberculosis.Status: Recruiting, Estimated PCD: 2025-02-23